Is there a role for neoadjuvant targeted therapy to downsize primary tumors for organ sparing strategies in renal cell carcinoma?

International Journal of Surgical Oncology

Volumn 2012, Issue , 2012, Pages

  Bex, A ^a   Kroon, B K ^a   De Bruijn, R ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84866146918     PISSN: 20901402     EISSN: 20901410     Source Type: Journal    
DOI: 10.1155/2012/250479     Document Type: Review

References (47)

1. Sun M., Abdollah F., Bianchi M., Trinh Q. D., Jeldres C., Thuret R., Treatment management of small renal masses in the 21st century: a paradigm shift. Annals of Surgical Oncology. In press
2. Yang G., Villalta J. D., Meng M. V., Whitson J. M., Evolving practice patterns forthe management of small renal masses in the USA. BJU International. In press
3. Guillotreau J., Haber G.-P., Autorino R., Miocinovic R., Hillyer S., Hernandez A., Laydner H., Yakoubi R., Isac W., Long J.-A., Stein R. J., Kaouk J. H., Robotic partial nephrectomy versus laparoscopic cryoablation for the small renal mass. European Urology 2012 61 5 899 904 2-s2.0-84859427013 10.1016/j.eururo.2012.01.007
4. Kunkle D. A., Uzzo R. G., Cryoablation or radiofrequency ablation of the small renal mass: a meta-analysis. Cancer 2008 113 10 2671 2680 2-s2.0-55849148450 10.1002/cncr.23896
5. Kunkle D. A., Egleston B. L., Uzzo R. G., Excise, ablate or observe: the small renal mass dilemma-a meta-analysis and review. Journal of Urology 2008 179 4 1227 1234 2-s2.0-40849102328 10.1016/j.juro.2007.11.047
6. Go A. S., Chertow G. M., Fan D., McCulloch C. E., Hsu C. Y., Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. The New England Journal of Medicine 2004 351 13 1296 1305 2-s2.0-4644221457 10.1056/NEJMoa041031 (Pubitemid 39268908)
7. Miller D. C., Schonlau M., Litwin M. S., Lai J., Saigal C. S., Renal and cardiovascular morbidity after partial or radical nephrectomy. Cancer 2008 112 3 511 520 2-s2.0-38749092963 10.1002/cncr.23218 (Pubitemid 351186192)
8. Kates M., Badalato G. M., Pitman M., McKiernan J. M., Increased risk of overall and cardiovascular mortality after radical nephrectomy for renal cell carcinoma 2 cm or less. Journal of Urology 2011 186 4 1247 1253 2-s2.0-80052732696 10.1016/j.juro.2011.05.054
9. Weight C. J., Lieser G., Larson B. T., Gao T., Lane B. R., Campbell S. C., Gill I. S., Novick A. C., Fergany A. F., Partial nephrectomy is associated with improved overall survival compared to radical nephrectomy in patients with unanticipated benign renal tumours. European Urology 2010 58 2 293 298 2-s2.0-77954489927 10.1016/j.eururo.2010.04.033
10. Touijer K., Jacqmin D., Kavoussi L. R., Montorsi F., Patard J. J., Rogers C. G., Russo P., Uzzo R. G., Van Poppel H., The expanding role of partial nephrectomy: a critical analysis of indications, results, and complications. European Urology 2010 57 2 214 222 2-s2.0-72149132532 10.1016/j.eururo.2009.10. 019
11. Van Poppel H., Da Pozzo L., Albrecht W., Matveev V., Bono A., Borkowski A., Colombel M., Klotz L., Skinner E., Keane T., Marreaud S., Collette S., Sylvester R., A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. European Urology 2011 59 4 543 552 2-s2.0-79952280398 10.1016/j.eururo.2010.12.013
12. Ljungberg B., Cowan N. C., Hanbury D. C., Hora M., Kuczyk M. A., Merseburger A. S., Patard J. J., Mulders P. F. A., Sinescu I. C., EAU guidelines on renal cell carcinoma: the 2010 update. European Urology 2010 58 3 398 406 2-s2.0-77955493600 10.1016/j.eururo.2010.06.032
13. Okhunov Z., Rais-Bahrami S., George A. K., Waingankar N., Duty B., Montag S., Rosen L., Sunday S., Vira M. A., Kavoussi L. R., The comparison of three renal tumor scoring systems: C-index, P.A.D.U.A., and R.E.N.A.L. nephrometry scores. Journal of Endourology 2011 25 12 1921 1924 2-s2.0-82455179572 10.1089/end.2011.0301
14. Ficarra V., Novara G., Secco S., Macchi V., Porzionato A., De Caro R., Artibani W., Preoperative Aspects and Dimensions Used for an Anatomical (PADUA) classification of renal tumours in patients who are candidates for nephron-sparing surgery. European Urology 2009 56 5 786 793 2-s2.0-70349267523 10.1016/j.eururo.2009.07.040
15. Kutikov A., Uzzo R. G., The R.E.N.A.L. nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth. Journal of Urology 2009 182 3 844 853 2-s2.0-68149183580 10.1016/j.juro.2009.05. 035
16. Zagoria R. J., Pettus J. A., Rogers M., Werle D. M., Childs D., Leyendecker J. R., Long-term outcomes after percutaneous radiofrequency ablation for renal cell carcinoma. Urology 2011 77 6 1393 1397 2-s2.0-79957924604 10.1016/j.urology.2010.12.077
17. Ansari J., Doherty A., McCafferty I., Wallace M., Deshmukh N., Porfiri E., Neoadjuvant sunitinib facilitates nephron-sparing surgery and avoids long-term dialysis in a patient with metachronous contralateral renal cell carcinoma. Clinical Genitourinary Cancer 2009 7 2 E39 E41 2-s2.0-70449427408 10.3816/CGC.2009.n.021
18. Motzer R. J., Bukowski R. M., Targeted therapy for metastatic renal cell carcinoma. Journal of Clinical Oncology 2006 24 35 5601 5608 2-s2.0-33846821872 10.1200/JCO.2006.08.5415 (Pubitemid 46631341)
19. Hutson T. E., Bukowski R. M., Cowey C. L., Figlin R., Escudier B., Sternberg C. N., Sequential use of targeted agents in the treatment of renal cell carcinoma. Critical Reviews in Oncology/Hematology 2011 77 1 48 62 2-s2.0-78650306863 10.1016/j.critrevonc.2010.07.018
20. Vogelzang N. J., Samlowski W., Weissman A., Long-term response in primary renal cancer to sequential antiangiogenic therapy. Journal of Clinical Oncology 2009 27 26 e106 e107 2-s2.0-70349331487 10.1200/JCO.2009.23.4021
21. Abel E. J., Culp S. H., Tannir N. M., Matin S. F., Tamboli P., Jonasch E., Wood C. G., Primary tumor response to targeted agents in patients with metastatic renal cell carcinoma. European Urology 2011 59 1 10 15 2-s2.0-78650246687 10.1016/j.eururo.2010.09.034
22. Jonasch E., Wood C. G., Matin S. F., Tu S. M., Pagliaro L. C., Corn P. G., Aparicio A., Tamboli P., Millikan R. E., Wang X., Araujo J. C., Arap W., Tannir N., Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. Journal of Clinical Oncology 2009 27 25 4076 4081 2-s2.0-70249115638 10.1200/JCO.2008.21.3660
23. Powles T., Kayani I., Blank C., Chowdhury S., Horenblas S., Peters J., Shamash J., Sarwar N., Boletti K., Sadev A., O'Brien T., Berney D., Beltran L., Haanen J., Bex A., The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancer. Annals of Oncology 2011 22 5 1041 1047 2-s2.0-79955512251 10.1093/annonc/mdq564
24. Yuasa T., Urakami S., Yamamoto S., Yonese J., Nakano K., Kodaira M., Takahashi S., Hatake K., Inamura K., Ishikwa Y., Fukui I., Tumor size is a potential predictor of response to tyrosine kinase inhibitors in renal cell cancer. Urology 2011 77 4 831 835 2-s2.0-79953906199 10.1016/j.urology.2010.12. 008
25. Bex A., Blank C., Meinhardt W., van Tinteren H., Horenblas S., Haanen J., A phase II study of presurgical sunitinib in patients with metastatic clear-cell renal carcinoma and the primary tumor in situ. Urology 2011 78 4 832 837 2-s2.0-79960690501 10.1016/j.urology.2011.05.034
26. Cowey C. L., Amin C., Pruthi R. S., Wallen E. M., Nielsen M. E., Grigson G., Watkins C., Nance K. V., Crane J., Jalkut M., Moore D. T., Kim W. Y., Godley P. A., Whang Y. E., Fielding J. R., Rathmell W. K., Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma. Journal of Clinical Oncology 2010 28 9 1502 1507 2-s2.0-77951886671 10.1200/JCO.2009.24.7759
27. Hellenthal N. J., Underwood W., Penetrante R., Litwin A., Zhang S., Wilding G. E., Teh B. T., Kim H. L., Prospective clinical trial of preoperative sunitinib in patients with renal cell carcinoma. Journal of Urology 2010 184 3 859 864 2-s2.0-77956642234 10.1016/j.juro.2010.05.041
28. Silberstein J. L., Millard F., Mehrazin R., Kopp R., Bazzi W., Diblasio C. J., Patterson A. L., Downs T. M., Yunus F., Kane C. J., Derweesh I. H., Feasibility and efficacy of neoadjuvant sunitinib before nephron-sparing surgery. BJU International 2010 106 9 1270 1276 2-s2.0-78349249825 10.1111/j.1464-410X.2010.09357.x
29. van der Veldt A. A. M., Meijerink M. R., van den Eertwegh A. J. M., Bex A., De Gast G., Haanen J. B. A. G., Boven E., Sunitinib for treatment of advanced renal cell cancer: primary tumor response. Clinical Cancer Research 2008 14 8 2431 2436 2-s2.0-42249091688 10.1158/1078-0432.CCR-07-4089 (Pubitemid 351551077)
30. Gorin M. A., Ekwenna O., Soloway M. S., Ciancio G., Dramatic reduction in tumor burden with neoadjuvant sunitinib prior to bilateral nephron-sparing surgery. Urology 2012 79 2 e11 2-s2.0-79958112550 10.1016/j.urology.2011.04.018
31. Hudes G., Carducci M., Tomczak P., Dutcher J., Figlin R., Kapoor A., Staroslawska E., Sosman J., McDermott D., Bodrogi I., Kovacevic Z., Lesovoy V., Schmidt-Wolf I. G. H., Barbarash O., Gokmen E., O'Toole T., Lustgarten S., Moore L., Motzer R. J., Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. The New England Journal of Medicine 2007 356 22 2271 2281 2-s2.0-34249779568 10.1056/NEJMoa066838 (Pubitemid 46849157)
32. Bex A., Jonasch E., Kirkali Z., Mejean A., Mulders P., Oudard S., Patard J. J., Powles T., Van Poppel H., Wood C. G., Integrating surgery with targeted therapies for renal cell carcinoma: current evidence and ongoing trials. European Urology 2010 58 6 819 828 2-s2.0-78049484272 10.1016/j.eururo.2010.08. 029
33. Escudier B., Roigas J., Gillessen S., Harmenberg U., Srinivas S., Mulder S. F., Fountzilas G., Peschel C., Flodgren P., Maneval E. C., Chen I., Vogelzang N. J., Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma. Journal of Clinical Oncology 2009 27 25 4068 4075 2-s2.0-70249084594 10.1200/JCO.2008.20.5476
34. US National Institutes of Health, Pazopanib Hydrochloride Before Surgery in Treating Patients With Kidney Cancer. ClinicalTrials gov 2012
35. US National Institutes of Health, Neoadjuvant pazopanib in renal cell carcinoma. ClinicalTrials gov 2012
36. US National Institutes of Health, Neoadjuvant Axitinib in Locally Advanced Renal Cell Carcinoma (RCC). ClinicalTrials gov 2012
37. Margulis V., Matin S. F., Tannir N., Tamboli P., Swanson D. A., Jonasch E., Wood C. G., Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma. Journal of Urology 2008 180 1 94 98 2-s2.0-44649192971 10.1016/j.juro.2008.03.047
38. Abel E. J., Culp S. H., Tannir N. M., Tamboli P., Matin S. F., Wood C. G., Early primary tumor size reduction is an independent predictor of improved overall survival in metastatic renal cell carcinoma patients treated with sunitinib. European Urology 2011 60 6 1273 1279 2-s2.0-79960483480 10.1016/j.eururo.2011.07.008
39. Bex A., van der Veldt A. A. M., Blank C., van den Eertwegh A. J. M., Boven E., Horenblas S., Haanen J., Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: initial experience with downsizing to reconsider cytoreductive surgery. World Journal of Urology 2009 27 4 533 539 2-s2.0-68549091054 10.1007/s00345-008-0368-7
40. Bex A., van der Veldt A. A. M., Blank C., Meijerink M. R., Boven E., Haanen J. B. A. G., Progression of a caval vein thrombus in two patients with primary renal cell carcinoma on pretreatment with sunitinib. Acta Oncologica 2010 49 4 520 523 2-s2.0-77951251917 10.3109/02841860903521111
41. Ebos J. M. L., Lee C. R., Cruz-Munoz W., Bjarnason G. A., Christensen J. G., Kerbel R. S., Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009 15 3 232 239 2-s2.0-60649087564 10.1016/j.ccr.2009.01.021
42. Conley S. J., Gheordunescu E., Kakarala P., Newman B., Korkaya H., Heath A. N., Clouthier S. G., Wicha M. S., Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proceedings of the National Academy of Sciences of the United States of America 2012 109 8 2784 2789 2-s2.0-84857407549 10.1073/pnas.1018866109
43. Cooke V. G., LeBleu V. S., Keskin D., Khan Z., O'Connell J. T., Teng Y., Duncan M. B., Xie L., Maeda G., Vong S., Sugimoto H., Rocha R. M., Damascena A., Brentani R. R., Kalluri R., Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway. Cancer Cell 2012 21 1 66 81 2-s2.0-84855912001 10.1016/j.ccr.2011.11. 024
44. Powles T., Blank C., Chowdhury S., Horenblas S., Peters J., Shamash J., Sarwar N., Boleti E., Sahdev A., O'Brien T., Berney D., Beltran L., Nathan P., Haanen J., Bex A., The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer. European Urology 2011 60 3 448 454 2-s2.0-79960977418 10.1016/j.eururo.2011.05.028
45. Long C. J., Canter D. J., Kutikov A., Li T., Simhan J., Smaldone M., Teper E., Viterbo R., Boorjian S. A., Chen D. Y. T., Greenberg R. E., Uzzo R. G., Partial nephrectomy for renal masses ≥ 7 cm: technical, oncological and functional outcomes. BJU International 2012 109 10 1450 1456 2-s2.0-84860334132 10.1111/j.1464-410X.2011.10608.x
46. Harris C. R., Whitson J. M., Meng M. V., Under-grading of 4 cm renal masses on renal biopsy. BJU International. In press
47. Tobert C. M., Uzzo R. G., Wood C. G., Lane B. R., Adjuvant and neoadjuvant therapy for renal cell carcinoma: a survey of the Society of Urologic Oncology. Urologic Oncology. In press